Inhibition of Cell Proliferation and Cell Viability by Sinecatechins in Cutaneous SCC Cells Is Related to an Imbalance of ROS and Loss of Mitochondrial Membrane Potential
Open Access
- 21 July 2022
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 11 (7) , 1416
Abstract
The term sinecatechins designates an extract containing a high percentage of catechins obtained from green tea, which is commercially registered as Veregen or Polyphenon E (PE) and may be considered for treatment of cutaneous squamous cell carcinoma (cSCC) and actinic keratosis (AK). As shown here, treatment of four cSCC cell lines with 200 µg/mL of PE resulted in strong, dose-dependent decrease in cell proliferation (20–30%) as well as strongly decreased cell viability (4–21% of controls, 48 h). Effects correlated with loss of mitochondrial membrane potential, whereas early apoptosis was less pronounced. At the protein level, some activation of caspase-3 and enhanced expression of the CDK inhibitor p21 were found. Loss of MMP and induced cell death were, however, largely independent of caspases and of the proapoptotic Bcl-2 proteins Bax and Bak, suggesting that sinecatechins induce also non-apoptotic, alternative cell death pathways, in addition to apoptosis. Reactive oxygen species (ROS) were downregulated in response to PE at 4 h, followed by an increase at 24 h. The contributory role of initially reduced ROS was supported by the antioxidant N-acetyl cysteine, which in combination with PE further enhanced the negative effects on cell viability. Thus, sinecatechins inhibited cell proliferation and viability of cSCC cells, which could suggest the use of PE for AK treatment. The mechanisms appear as linked to an imbalance of ROS levels.Keywords
Funding Information
- European skin cancer foundation (ESCF) (S0251/10015/2020)
This publication has 64 references indexed in Scilit:
- ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosisCell Death & Disease, 2013
- Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I’ modeCell Death & Disease, 2013
- Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on BakOncogene, 2011
- Regulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to CancerBiochemistry, 2011
- The BCL-2 Family ReunionMolecular Cell, 2010
- RETRACTED: The Bmi-1 polycomb protein antagonizes the (−)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survivalCarcinogenesis, 2009
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- (−)-Epigallocatechin Gallate and Polyphenon E Inhibit Growth and Activation of the Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Signaling Pathways in Human Colon Cancer CellsClinical Cancer Research, 2005
- Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2001
- p21 is a universal inhibitor of cyclin kinasesNature, 1993